UK-based biopharmaceutical company raises $75m in IPO
Achilles Therapeutics, a UK-based biopharmaceutical company developing precision T cell therapies to treat solid tumours, has floated on the Nasdaq stock exchange to raise $175.5m.
At the end of March, Achilles priced its initial public offering (IPO) of 9.75 million American depositary shares at $18 apiece, which was the midpoint of the $17 to $19 per share range it had previously set. It closed on the first day of trading at $16 per share to give a market capitalisation of $946m.
…
